Market Scenario-
Market
Research Future (MRFR)’s newly released study reveals that the Urinary Tract
Infection Market share is projected to reach USD 12.21 billion by 2032 at a
CAGR of 3.5% from 2023 to 2032. The market valuation by the end of the analysis
period will be around USD 11.3 billion, adds the extensive report.
Competitive Analysis-
Urinary
Tract Infection Market players are included in
Allergan,
Eli Lily, Company,
GlaxoSmithKline plc,
Cipla Inc.,
Pfizer Inc.,
Novo Nordisk A/S,
Bayer AG,
Novartis Ag,
Teva Pharmaceuticals,
Merck & Co. Inc.
are
identified as the top Urinary Tract Infection Market Players highlighted in the
extensive study.
Primary Boosters and Barriers
Rising
investments in exhaustive research & development of novel drugs and
advanced devices could be a crucial growth inducer of the market growth in the
years ahead. Majority of the companies are focused on carrying out
extensive R&D activities for antibiotics. The key firms in the market part
of these research studies include Cipla, Pfizer, and GlaxoSmithKline, investing
substantially in antibacterial discovery trials.
The Urinary Tract
Infection Market Report Size is slated to experience
significant upsurge in the coming years, due to the surging burden of UTIs
among women in the reproductive age group. A few other risk aspects include the
utilization of contraceptive diaphragms,
urinary tract abnormalities, and menopause, which are
developing rapidly among the female population worldwide. This will be a major
reason behind the robust business expansion in the ensuing years.
Striking
increase in cases of diabetes and obesity and the consequent development of
bladder dysfunction, paired with the surging use of cutting-edge technologies
like nanotechnology stimulates the market growth as well.
Segmental Analysis
Drug
class, application, pathogen, and end-user are the segments depending on which
the urinary tract
infections market overview has been considered in the review
study.
- Drug class-based
segments outlined
in the study are aminoglycosides, quinolones, azoles, along with
cephalosporins, and penicillin. Quinolones-wise, the major segments are
pefloxacin, enoxacin, fleroxacin, and norfloxacin.
- Applications of urinary
tract infection drugs and devices are in urethritis, cystitis,
pyelonephritis, and others. Urethritis can expect the highest growth in
the forthcoming period.
- Pathogens studied in the
report are Proteus mirabilis, klebsiella pneumonia, escherichia coli, and
more.
- Market end-users are
healthcare centres, hospitals, self-administered kits, and clinics.
Regional Status
North
America presides over the worldwide market for urinary tract infections, in
terms of revenue generation. The North American market should continue to
create waves over the following years, thanks to the soaring cases of diabetes
and various chronic disorders. The mushrooming UTI patient base, particularly
in the United States further fosters the industry share in the region. Studies
have revealed that over 40 million Americas have diabetes, with more than 11%
of the population in the US, resulting in higher vulnerability to infections
such as UTIs. Vast pool of public health laboratories providing extensive
services for UTI testing, paired with the availability of medical insurance are
also a few other important growth boosters.
Asia
Pacific will be covering considerable grounds at the fastest pace from 2020 to
2027, as the healthcare infrastructure continues to improve and cases of
diabetes and UTI cases mounting in India, Malaysia, Singapore, and China. The
mounting number of urinary tract infection testing, paired with the stunning
expansion of the biopharma and pharma industries could further boost the
business value in the region over the years to come. Experts believe that Asia
Pacific will be a prime spot for the market, given the tremendous growth of the
medical tourism industry across India and Japan. Other growth opportunities in
the region will be the rapidly aging populace, surge in consumer awareness,
rise in kidney diseases, supportive government policies, and the upgradation of
the healthcare infrastructure.
Related reports-
About US:
Market
Research Future (MRFR) enable customers to unravel the complexity of various
industries through Cooked Research Report (CRR), Half-Cooked Research Reports
(HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market
Research & Consulting Services.
Contact us:
Market
Research Future (part of Wantstats Research and Media Private Limited),
99
Hudson Street,5Th Floor, New York,
New
York 10013
